1 / 2

Vaccine Adjuvants Market worth 769.4 Million USD by 2021

The global vaccine adjuvants market consists of human and veterinary adjuvants that are used to improve the efficacy of vaccines. This market is driven by several factors such as increasing government funding for research, high prevalence of diseases, expanding biotechnology and biopharmaceutical industries, and growing focus on prevention of diseases. The high growth potential in emerging markets has opened an array of opportunities for the market. However, the high cost of adjuvant-based research and proven safety of adjuvants are hampering the growth of the global market.

Download Presentation

Vaccine Adjuvants Market worth 769.4 Million USD by 2021

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Vaccine Adjuvants Market - Increasing Use of Adjuvants in Vaccine and Preventable Diseases Drives the Market Growth The report "Vaccine Adjuvants Market by Product Type (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Forecasts to 2021”, The global vaccine adjuvants market is expected to reach USD 769.4 Million by 2021 from USD 467.0 Million in 2016 at a CAGR of 10.5% from 2016 to 2021. Browse 90 market data tables with 42 figures spread through 156 pages and in-depth TOC on "Vaccine Adjuvants Market by Product Type (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Forecasts to 2021" http://www.marketsandmarkets.com/Market-Reports/vaccine-adjuvants-market-152603894.html Early buyers will receive 10% customization on reports. Industry Insights: Industry growth is driven by increasing government funding for research, high prevalence of diseases, expanding biotechnology and biopharmaceutical industries, and growing focus on prevention of diseases. The high growth potential in emerging markets has opened an array of opportunities for the market. However, the high cost of adjuvant-based research and proven safety of adjuvants are hampering the growth of the global market. Get The PDF Brochure For This Report: http://www.marketsandmarkets.com/pdfdownload.asp?id=152603894 Geographical Scenario: Based on geography, the vaccine adjuvants market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). However, Asia is projected to grow at the highest CAGR during the forecast period. Growth in the North American segment is primarily driven by the increasing geriatric population and rising incidences of diseases in the North American countries. Request Sample: http://www.marketsandmarkets.com/requestsample.asp?id=152603894 Industry Leaders: The prominent players in the Vaccine Adjuvants Market are Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc. (U.S.), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), MPV Technologies (U.S.), and OZ Biosciences (France). Stakeholders:       Vaccine adjuvants manufacturers and suppliers Academic research institutes Biopharmaceutical and biotechnology companies Research and development (R&D) companies Business research and consulting service providers Medical research laboratories

  2. Academic medical centers and universities About MarketsandMarkets™: MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Contact: Mr. Rohan MarketsandMarkets™ 701 Pike Street Suite 2175, Seattle, WA 98101, United States Tel: 1-888-600-6441

More Related